Oncopeptides publishes Q1 report 2022
STOCKHOLM — May 4, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today publishes the report for the first quarter 2022.“It is with growing enthusiasm and confidence in our data that we enter into 2022”, says Jakob Lindberg, CEO of Oncopeptides. “The first quarter has been characterized by regulatory interactions in Europe and the US. The outcome of these interactions will have significant implications on the future direction of the Company, and our ability to continue